hGH

Mechanism

Growth hormone helps regulate growth and metabolism. Prescription treatment can replace a deficiency or treat certain growth disorders in children. Some products have other specific uses, such as HIV-related wasting or short bowel syndrome.^359,360,361

Medicine	What it contains
Daily somatropin	Recombinant human growth hormone. Approved uses vary by brand and country.
Sogroya	Somapacitan, a modified growth hormone that binds to albumin in the blood.
Skytrofa	Lonapegsomatropin, a prodrug that releases somatropin.
Ngenla	Somatrogon, a growth hormone fusion protein.

Is weekly better?

Each weekly product has its own trials. A result for one is not a result for all three.

Children with growth hormone deficiency

In REAL4, 200 children received weekly somapacitan or daily growth hormone. Height velocity at 52 weeks was 11.2 versus 11.7 cm per year. The trial tested whether weekly treatment was acceptably close to daily treatment, not whether it was better.³⁶²

Comparison of a weekly product

In the Skytrofa trial, 161 children had height velocities of 11.2 cm per year with weekly lonapegsomatropin and 10.3 with daily treatment at 52 weeks. The estimated difference was 0.9 cm per year, with a 95% confidence interval of 0.2 to 1.5. That result belongs to this product and this trial.³⁶³

Additional product comparison

The Ngenla trial enrolled 224 children. Height velocity at 52 weeks was 10.1 cm per year with weekly somatrogon and 9.8 with daily treatment. Growth was the primary outcome.³⁶⁴

Comparator study

The trial reported dose-specific results for its lower and higher daily-dose groups.

142 children

At 52 weeks, height velocity was 11.0 cm per year with weekly somapacitan, 9.4 with the lower daily dose and 11.1 with the higher daily dose. The weekly treatment outperformed the lower daily dose, but not the higher one.³⁶²

Keep the groups together

There were 70 children in the weekly group, 37 in the lower-dose daily group and 35 in the higher-dose daily group. Quoting only the lower-dose comparison would leave out an important part of the trial.³⁶²

Annual growth-rate outcome

These results describe growth over a year in children with a specific diagnosis. They do not show how much taller an adult with closed growth plates could become. Somatropin is not used to promote growth once the growth plates have closed.^362,359

An adult trial missed its target

A positive conclusion can hide a negative primary result.

Primary endpoint not met

A phase 3 study published in 2026 randomized 202 adults; 198 received treatment. At 26 weeks, trunk fat mass changed by -0.37 kg with weekly somatrogon and +0.03 kg with placebo. The difference was not statistically significant (p=0.0821).³⁶⁵

Some other measurements improved

The study reported improvements in lean body mass and some other body-composition measures. Several analyses were secondary or added after the main analysis plan. Those findings do not erase the missed primary endpoint.³⁶⁵

Adult research and pediatric approval

The current US Ngenla label covers children aged 3 years and older with growth hormone deficiency. It does not include adults. The adult study concerns a population outside the pediatric approval.³⁶⁴

Replacement outcomes

Adult replacement studies and healthy-adult studies enrolled distinct populations.

Body composition

A meta-analysis included 22 placebo-controlled trials involving 591 adults given growth hormone and 562 given placebo. At six months, lean body mass increased by 2.61 kg with growth hormone and 0.04 kg with placebo; fat mass changed by -2.19 kg and +0.31 kg. These results concern adults with diagnosed growth hormone deficiency.³⁶⁶

The result has limits

Lean body mass includes more than skeletal muscle. Changes in body composition and cholesterol do not, by themselves, establish greater strength, fewer heart attacks or a longer life. More treatment is not automatically better treatment.³⁶⁶

Weekly adult treatment

Adult Sogroya and Skytrofa trials also measured body composition. Their daily-growth-hormone comparison groups did not have formal statistical comparisons with the weekly groups in the current US labels. A reader should not treat those trial arms as proof that every weekly product beats daily replacement.^362,363

Anti-aging and performance

Lean mass, strength and longevity are distinct endpoints.

Healthy older adults

A systematic review found small body-composition changes across 18 study populations; 220 growth-hormone recipients completed the studies. Fat mass fell by about 2.1 kg and lean mass rose by about 2.1 kg compared with controls, without a significant weight change. Swelling, joint pain, carpal tunnel symptoms and breast enlargement were more common.³⁶⁷

Healthy younger adults

A 2017 review of 11 studies involving 254 people found increased lean mass and reduced fat mass, but no improvement in muscle strength or maximum oxygen uptake over weeks to months. One study found an improvement in anaerobic capacity. The evidence should not be reduced to either “proven performance enhancer” or “no measured effect at all.”³⁶⁸

The old anti-aging headline

A frequently cited 1990 study involved 21 men aged 61 to 81, with 12 receiving growth hormone. It measured body composition and other physical markers over six months of treatment. It did not show that growth hormone reverses aging or extends life.³⁶⁹

Long-term follow-up

Later risk estimates depend on the original diagnosis and treatment setting.

24,232 patients

The SAGhE cohort followed people treated with growth hormone during childhood for more than 400,000 patient-years. It compared later mortality with expected rates in the general population. This was an observational study, not a randomized trial.³⁷⁰

The lower-risk group

Among people with isolated growth hormone deficiency or idiopathic short stature, overall mortality was not significantly increased. The standardized mortality ratio was 1.1, with a 95% confidence interval of 0.9 to 1.3.³⁷⁰

Underlying illness changes the picture

Overall mortality was higher in groups with more serious underlying conditions. Some cause-specific mortality was increased across groups, and the authors called for continued long-term surveillance. The underlying illnesses complicate comparisons of treatment risk.³⁷⁰

Side effects and serious risks

A replacement treatment still needs clinical monitoring.

Effects people may notice

Fluid retention, joint pain and carpal tunnel symptoms can occur. Growth hormone can also reduce insulin sensitivity and reveal or worsen diabetes. Symptoms alone cannot determine whether the medicine or dose is appropriate.³⁵⁹

Warnings that need attention

The label describes intracranial hypertension, pancreatitis and, in growing children, slipped capital femoral epiphysis with or without osteonecrosis. A new limp or hip or knee pain needs medical assessment. Severe headache with vision changes also needs prompt assessment.³⁵⁹

Cancer history

Active malignancy is a contraindication. Second tumors, especially meningiomas, have been reported in childhood cancer survivors treated with growth hormone, particularly after head radiation.³⁵⁹

Critical-illness setting

Trials in 522 critically ill adults without growth hormone deficiency found mortality of 42% with pharmacologic growth hormone and 19% with placebo. These patients and doses were very different from routine outpatient replacement. The finding should not be presented as the death rate for standard deficiency treatment.³⁵⁹

Country approvals

The product label and date both define the scope of these records.

The US changed in 2026

On February 27, 2026, FDA approved Sogroya for additional pediatric growth conditions: being born small for gestational age without catch-up growth, Noonan syndrome and idiopathic short stature. The current US label also includes growth hormone deficiency in children and adults.^371,362

Europe: authorization status

The EMA committee issued a positive opinion on the additional conditions on September 17, 2026. At this September 30 check, the final European Commission decision had not been verified, and the retrieved EU product information still listed growth hormone deficiency. A positive opinion is not the same as a completed authorization.^372,373

Canada: product label

Canada's Sogroya monograph, authorized May 22, 2026, lists growth hormone deficiency in children aged 2.5 years and older and in adults. The added US indications should not be assumed to apply elsewhere.³⁷⁴

Product quality, law and sport

Medical approval covers named indications rather than every growth-hormone claim.

Anti-aging and bodybuilding

FDA states that growth hormone is not approved for anti-aging, bodybuilding or athletic enhancement. US law also places specific restrictions on distribution for human use. This is more precise than saying that every instance of possession is automatically a federal crime.^375,376

Compounding status

FDA states that biological products such as growth hormone do not qualify for the usual 503A or 503B compounding exemptions. Separate rules for handling approved products do not establish approval of a compounded growth hormone product.^377,375

A specific 2026 recall

Health Canada recalled two Omnitrope lots in July 2026 because cartridges could crack. The risks included leakage, contamination, glass injury and receiving too little medicine.³⁷⁸

Banned in covered sport

WADA's current 2026 list prohibits growth hormone, its analogues and fragments at all times. The published 2027 list keeps them prohibited. A prescription does not automatically satisfy anti-doping rules.^379,380

China, Russia and Japan

Regional records include a sponsor submission, observational cohort and uncontrolled switch study.

The weekly product in China

A sponsor's public reimbursement submission for Yipei reported 52-week growth velocity of 9.910 cm per year with the weekly product and 10.037 with daily growth hormone in children with growth hormone deficiency. This was a noninferiority comparison. The document is hosted by China's National Healthcare Security Administration, but the trial summary was submitted by the applicant; it is not an independent assessment of every claim.³⁹⁰

Long-running clinical care in Russia

A Russian report described 254 children identified over a 20-year period, of whom 218 had completed treatment. It reported mean first-year growth of 11.5 cm during replacement treatment. The study was observational, used different products over time and included other hormone replacement.³⁹¹

A small switching study in Japan

A 2026 study followed 12 adults for two years after they switched from daily growth hormone to weekly somapacitan. Several metabolic measurements improved, but HbA1c did not. The uncontrolled switching study reports within-group changes; it cannot attribute them to the switch or show that weekly treatment is better.³⁹²

Common questions

Diagnosis, growth, body composition, safety and product differences.

01 What is HGH, and who is it actually for?

HGH usually means human growth hormone; current prescription products include daily somatropin and distinct long-acting growth hormone medicines. They are used for diagnosed growth hormone deficiency and other named product-specific conditions, not as one general anti-aging or performance drug. Serostim and Zorbtive are somatropin products with separate HIV-wasting and short-bowel indications.^{359,362,363,364,360,361}

02 How do doctors test for growth hormone deficiency?

Most adults suspected of growth hormone deficiency need confirmation with a stimulation test; an Endocrine Society guideline makes an exception when a persistent genetic or structural cause from childhood is already proven. A pediatric guideline says diagnosis can overlap across growth hormone deficiency, idiopathic short stature, and primary IGF-I deficiency, so assessment must be individualized. The exact test and cutoff belong to a specialist.^381,382

03 Can HGH make someone taller after growth plates close?

No, once growth plates are closed, linear bone growth has ended. Current pediatric growth labels do not support treatment for growth promotion after the epiphyses have closed. GH can still change fluid and body composition, which is not the same as becoming taller.^{359,362,363,364}

04 How long does growth hormone take to work?

No single timeline applies across outcomes and populations. Adult deficiency trials measured body composition over six months, while separate pediatric weekly trials measured growth over 52 weeks. A clinician follows the endpoint tied to the diagnosis, product, and age rather than an enhancement timeline.^{366,362,363,364}

05 Are daily and weekly growth hormone products interchangeable?

No. Somapacitan-beco and somatrogon-ghla are long-acting analogs, while lonapegsomatropin-tcgd is a prodrug that releases somatropin; each has its own label, device, population, missed-dose rules, and trial program. Weekly and daily products cannot be swapped milligram for milligram.^{359,362,363,364}

06 What side effects should I watch for?

Current labels warn about swelling, joint or muscle pain, carpal tunnel symptoms, headache from intracranial hypertension, pancreatitis, glucose intolerance, and product- or population-specific risks. A limp or persistent hip or knee pain in a growing child is a label warning for slipped capital femoral epiphysis, and severe obesity or airway problems create a separate warning in children with Prader-Willi syndrome. The relevant warning depends on the exact product and diagnosis.^{359,362,363,364}

07 Can HGH cause diabetes?

Yes, growth hormone can reduce insulin sensitivity, and current labels warn that glucose intolerance or diabetes may appear or worsen, especially in people with risk factors. The healthy-elderly review also found possible glucose-related harm, but it does not give an individual risk rate. Product labels call for glucose monitoring in at-risk patients.^359,362,367

08 Does HGH raise cancer risk?

Growth hormone should not be used with active cancer. A review of childhood-treatment studies found no clear increase in overall cancer incidence, but did find more second tumors; differences in underlying illness and previous cancer treatment make the cause difficult to separate. Cancer survivors need an individual review, especially after head radiation.^359,383,384

09 Does HGH reverse aging or help people live longer?

No human trial in the cited evidence showed that HGH makes healthy people live longer. The famous 1990 study had 12 treated older men and 9 untreated men and measured body composition for six months; lifespan and broad healthy aging were outside its outcomes. A later review found small body-composition changes, more adverse effects, and no basis to recommend GH as anti-aging treatment.^369,367

10 Does HGH build muscle or improve strength?

HGH can increase measured lean mass in healthy young adults, but that did not translate into better strength or maximum oxygen uptake across 11 placebo-controlled studies with 254 participants. One study did find improved anaerobic exercise capacity. Lean mass can also include fluid and other non-fat tissue.³⁶⁸

11 What if I miss a dose or the medicine gets warm?

The labels use different missed-dose windows and temperature limits. Sogroya and Ngenla describe a missed weekly dose within three days, while Skytrofa uses two days; their room-temperature and after-opening rules also differ. The labels say to use the exact product instructions and contact the prescriber or pharmacist if the window or temperature limit was exceeded.^{362,363,364,359}

12 How is HGH different from sermorelin, tesamorelin, CJC-1295, or ipamorelin?

They are different compounds. Prescription HGH products provide growth-hormone receptor activity directly; sermorelin, tesamorelin, and CJC-1295 are based on growth hormone-releasing hormone, while ipamorelin is a different growth hormone secretagogue. Evidence for one does not establish the benefits or risks of another.^{359,385,386,387,388}

13 Do HGH pills, sprays, or supplements work?

The current US product records are prescription injections; they do not establish an approved HGH pill or nasal spray. Products sold as oral HGH or supplement boosters are not the same as somatropin or the weekly prescription medicines. FDA's April 2026 import alert also says hGH is not approved for anti-aging, bodybuilding, or athletic enhancement.^{359,362,363,364,375}

14 Is HGH banned in sport or illegal in the United States?

In tested sport, the 2026 WADA list prohibits GH and named analogs at all times unless the athlete has an approved therapeutic-use exemption. DEA's July 2026 fact sheet says hGH is not controlled under the federal Controlled Substances Act, while federal law at 21 USC 333(e) separately penalizes knowing distribution or possession with intent to distribute for a use not authorized by HHS.^379,389,376

15 How much does prescription growth hormone cost, and does insurance cover it?

The source search did not verify current cash prices or insurer criteria. These prescription biologics have different labeled populations and devices, so coverage, prior authorization, pharmacy pricing, and assistance eligibility can be product- and plan-specific. The product labels establish medical scope, not payer policy.^{359,362,363,364}